Gene therapy
AAV vectors are the holy grail of gene therapy. These viral tools introduce "payload genes" into different tissues often with great precision. Aavogen's therapeutics are muscle-specific and were designed to avoid toxicities that have compromised other gene therapeutics. For this reason, their use has the potential to safely and durably treat different muscle and neuromuscular diseases.
Strong healthy muscle
Aavogen is developing gene therapeutics for muscle wasting diseases like inclusion body myositis, Duchenne muscular dystrophy and heart failure. Our therapeutics build muscle mass and strength, prevent degeneration and improve muscle function in different disease animal models and in engineered human muscle tissues.
Strong healthy hearts
Cardiac and skeletal muscle wasting go hand-in-hand. Indeed, addressing cardiac and respiratory failure is key to preventing mortality in many muscle wasting diseases. Aavogen's therapeutics prevent cardiac cachexia - the loss of cardiac muscle - and improve cardiac function at rest and during strenuous exercise.
At Aavogen, it's personal
Aavogen was founded by a family directly impacted by four muscle wasting diseases: Duchenne muscular dystrophy (DMD), cancer cachexia, COPD and spinocerebellar ataxia. Our fight is personal and our commitment to developing better and more effective therapies is undaunted.
This includes AVGN7 for inclusion body myositis and AVGN7+AVGND, a combinatorial featuring a "micro-dystrophin" gene therapeutic. This "one-two punch" is industry's only approach to preventing degeneration and building strength in subjects with DMD.
Patient outreach
We understand the challenges of fighting a muscle wasting disease. We also understand the role education plays in empowering patients.
If you have questions about Aavogen or AVGN7, about gene therapy or even different muscle wasting diseases, please contact us. You can also learn more about investing and collaborating with Aavogen by visiting the link to the right.
Whether you're curious, scared or intrigued, we want to hear from you.